{
    "clinical_study": {
        "@rank": "73875", 
        "acronym": "REGO-SARC", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an international (France, Austria and Germany), randomized, double-blind,\n      placebo-controlled, phase II study to evaluate the efficacy and safety of regorafenib in\n      patients with histologically proven metastatic and/or unresectable Soft Tissue Sarcoma (STS)\n      after failure or intolerance to doxorubicin (or other anthracycline).\n\n      Four strata will be defined:\n\n      Strata A: Liposarcoma Strata B: Leiomyosarcoma Strata C: Synovial sarcoma Strata D: other\n      sarcomas (see Appendix C) Approximately 192 patients who meet the eligibility criteria will\n      be randomly assigned in a 1:1 ratio to one of the treatment groups."
        }, 
        "brief_title": "Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Sarcoma", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "detailed_description": {
            "textblock": "The standard of care for metastatic soft tissue sarcoma is doxorubicin +/- ifosfamide. After\n      failure or intolerance to doxorubicin, there is no standard of care. In Europe, two are\n      currently approved for the treatment of soft tissue sarcoma after failure/intolerance to\n      doxorubicin: trabectedin (Yondelis\u00ae) for all histological subtype and pazopanib (Votrient \u00ae)\n      for all subtypes excluding liposarcomas. Nevertheless, none of these drugs improve the\n      overall survival over placebo.\n\n      The study is composed of 3 periods:\n\n        1. A Screening Period,\n\n        2. A Treatment Period,\n\n        3. And a Survival Follow-up Period. Patients randomized to be treated with regorafenib\n           will receive the treatment orally for 3 weeks of every 4 week (28 days) cycle (ie, 3\n           weeks on/1 week off).\n\n      Patients randomized to the placebo arm will be treated for 3 weeks of every 4 weeks cycle\n      (ie, 3 weeks on/1 week off).\n\n      In addition to the regorafenib and placebo treatments, patients will receive best supportive\n      care. Best supportive care includes any method to preserve the comfort and dignity of the\n      patients and excludes any disease-specific anti-neoplastic therapy such as any kinase\n      inhibitor,chemotherapy, radiation therapy, or surgical intervention.\n\n      Patients receiving placebo, who experience disease progression may be offered open-label\n      regorafenib(cross-over option)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years\n\n          -  Histological documentation of soft tissue sarcoma (including uterus)with available\n             Formalin Fixed Paraffin Embedded (FFPE) blocks\n\n          -  Prior treatment with doxorubicin or other anthracycline\n\n          -  Metastatic disease not amenable to surgical resection with curative intent\n\n          -  Documentation of progression within the last 6 months\n\n          -  Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT\n             scan as defined by RECIST 1.1.\n\n          -  Performance status \u22641(ECOG)\n\n          -  Life expectancy \u2264 3 months\n\n          -  Adequate bone marrow, renal, and hepatic function:\n\n          -  INR/PTT \u22641.5 x ULN Patients who are therapeutically treated with an agent such as\n             warfarin or heparin will be allowed to participate provided that no prior evidence of\n             underlying abnormality in coagulation parameters exists. Close monitoring will be\n             performed until INR/PTT is stable.\n\n          -  Women of childbearing potential and male patients must agree to use adequate\n             contraception for the duration of study participation and up to 3 months following\n             completion of therapy.\n\n          -  Recovery to NCI-CTCAE v4.0 Grade 0 or 1 level or recovery to baseline preceding the\n             prior treatment from any previous drug/procedure related toxicity (except alopecia,\n             anemia, and hypothyroidism).\n\n          -  In the assessment of the investigator, patient is able to comply with study\n             requirements\n\n          -  Signed, IRB-approved written informed consent\n\n        Exclusion Criteria:\n\n          -  More than 3 lines of systemic treatment for metastatic sarcoma\n\n          -  Histological subtypes listed in Appendix C (especially GIST, osseous sarcoma,\n             embryonal or alveolar rhabdomyosarcoma)\n\n          -  Primary bone sarcoma\n\n          -  Prior treatment with regorafenib\n\n          -  Known history of or concomitant malignancy likely to affect life expectancy in the\n             judgment of the investigator\n\n          -  Pregnant or breastfeeding patients. Women of childbearing potential must have a\n             pregnancy test performed before start of treatment\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             before start of treatment\n\n          -  Active cardiac disease including any of the following: Congestive heart failure\n             (NYHA) \u2265Class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun\n             within the last 3 months), Cardiac arrhythmias requiring anti-arrhythmic therapy\n             (beta blockers or digoxin are permitted)\n\n          -  Uncontrolled hypertension (SBP >150 mmHg or diastolic pressure >90 mmHg despite\n             optimal medical management)\n\n          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident\n             (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism\n             (within the last 6 months)\n\n          -  Ongoing infection >Grade 2 according to NCI-CTCAE v4.0\n\n          -  Known history of human immunodeficiency virus (HIV) infection\n\n          -  Known history of chronic hepatitis B or C\n\n          -  Patients with seizure disorder requiring medication\n\n          -  History of organ allograft\n\n          -  Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event > Grade 4\n             within 4 weeks of start of treatment\n\n          -  Non-healing wound, ulcer, or bone fracture\n\n          -  Renal failure requiring hemo- or peritoneal dialysis\n\n          -  Dehydration according to NCI-CTC v 4.0 Grade >1\n\n          -  Substance abuse, medical, psychological, or social conditions that may interfere with\n             the patient's participation in the study or evaluation of the study results\n\n          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients\n             in the formulation, including lactose\n\n          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed\n             consent\n\n          -  Inability to swallow, malabsorption condition\n\n          -  Pleural effusion or ascites that causes respiratory compromise (Grade 2 dyspnea)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "192", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900743", 
            "org_study_id": "REGO-SARC-1214"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.", 
                "intervention_name": "Regorafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sarcoma", 
            "Metastatic", 
            "Regorafenib"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }, 
                    "name": "Medizinische Universit\u00e4t Graz"
                }, 
                "investigator": {
                    "last_name": "Ferdinand PLONER, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Innsbruck", 
                        "country": "Austria", 
                        "zip": "6020"
                    }, 
                    "name": "Universit\u00e4tsklinik f\u00fcr Innere Medizin I"
                }, 
                "investigator": {
                    "last_name": "Wolfgang EISTERER, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "4010"
                    }, 
                    "name": "Krankenhaus der Barmherzigen Schwestern Linz"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "Elisabeth.Lindner@cecog.at", 
                    "last_name": "Elisabeth LINDER, Director SPA", 
                    "phone": "(43)1 409 77 25 19"
                }, 
                "contact_backup": {
                    "email": "marika.rosner@gmail.com", 
                    "last_name": "Marika ROSNER, CRA Monitor", 
                    "phone": "(43)1 409 77 25 19"
                }, 
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1090"
                    }, 
                    "name": "AKH-Wien"
                }, 
                "investigator": {
                    "last_name": "Thomas BRODOWICZ, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "oncologie-recherche-2@chu-besancon.fr", 
                    "last_name": "Ludivine ROY, CRA", 
                    "phone": "33 (0)3 81 66 92 31"
                }, 
                "facility": {
                    "address": {
                        "city": "Besancon", 
                        "country": "France", 
                        "zip": "25000"
                    }, 
                    "name": "H\u00f4pital St Jacques"
                }, 
                "investigator": [
                    {
                        "last_name": "Loic CHAIGNEAU, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Elsa KABACHER, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Thierry NGUYEN, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "m.dupouy@bordeaux-unicancer.fr", 
                    "last_name": "Christine DUPOUY, CRA", 
                    "phone": "33 (0)5 56 33 32 53"
                }, 
                "contact_backup": {
                    "email": "s.mathoulin@bordeaux-unicancer.fr", 
                    "last_name": "Simone MATHOULIN, MD", 
                    "phone": "33 (0)5 56 33 33 33"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "Institut Bergoni\u00e9"
                }, 
                "investigator": [
                    {
                        "last_name": "Antoine ITALIANO, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Guilhem ROUBAUD, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Binh BUI NGUYEN, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "b.griffon@baclesse.fr", 
                    "last_name": "B\u00e9n\u00e9dicte GRIFFON, Responsable URC", 
                    "phone": "33 (0)2 31 45 50 05"
                }, 
                "contact_backup": {
                    "email": "s.danet@baclesse.fr", 
                    "last_name": "Sophie DANET, CRA", 
                    "phone": "33 (0)2 31 45 50 02"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14076"
                    }, 
                    "name": "Centre Fran\u00e7ois Baclesse"
                }, 
                "investigator": [
                    {
                        "last_name": "Corinne DELCAMBRE, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Sabine NOAL, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "stiago@cgfl.fr", 
                    "last_name": "Sandrine TIAGO, Responsable URC", 
                    "phone": "33 (0)3 45 34 80 51"
                }, 
                "contact_backup": {
                    "email": "epetit@cgfl.fr", 
                    "last_name": "Erwan PETIT, CRA", 
                    "phone": "33 (0)3 80 73 77 52"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "Centre GF Leclercq"
                }, 
                "investigator": [
                    {
                        "last_name": "Nicolas ISAMBERT, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Isabelle DESMOUILINS, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "s-clisant@o-lambret.fr", 
                    "last_name": "St\u00e9phanie CLISANT, Responsable URC", 
                    "phone": "33 (0)3 20 29 59 35"
                }, 
                "contact_backup": {
                    "email": "s-courapied@o-lambret.fr", 
                    "last_name": "Sandy COURAPIED, CRA", 
                    "phone": "33 (0)3 20 29 59 35"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Centre Oscar Lambret"
                }, 
                "investigator": [
                    {
                        "last_name": "Nicolas PENEL, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Eric AMELA, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fr\u00e9d\u00e9rik LAESTAIUS, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Antoine ADENIS, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "christelle.florent@lyon-unicancer.fr", 
                    "last_name": "Christelle FLORENT, Responsable URC", 
                    "phone": "33 (0)4 78 78 27 72"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "investigator": [
                    {
                        "last_name": "Jean-Yves BLAY, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Isabelle-Laure RAY-COQUART, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Philippe CASSIER, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pierre BIRON, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pierre-Etienne HEUDEL, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "meriem.boualem@ap-hm.fr", 
                    "last_name": "Meriem BOUALEM, Responsable URC", 
                    "phone": "33 (0)4 91 38 46 05"
                }, 
                "contact_backup": {
                    "email": "josiane.onezime@ap-hm.fr", 
                    "last_name": "Josiane ONEZIME, CRA", 
                    "phone": "33 (0)4 91 38 46 05"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13354"
                    }, 
                    "name": "H\u00f4pital de La Timone"
                }, 
                "investigator": [
                    {
                        "last_name": "Florence DUFFAUD, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "S\u00e9bastien SALAS, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Thanh HUYNH, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bec@ipc-unicancer.fr", 
                    "last_name": "Dominique GENRE, MD", 
                    "phone": "33 (0)4 91 22 36 67"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }, 
                    "name": "Institut Paoli Calmettes"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7ois BERTUCCI, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "christine.gestin-boyer@icm-unicancer.fr", 
                    "last_name": "Christine GESTIN-BOYER, Responsable", 
                    "phone": "33 4 67612515"
                }, 
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34298"
                    }, 
                    "name": "Centre Val d'Aurelle"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "beatrice.saulquin@ico-unicancer.fr", 
                    "last_name": "B\u00e9atrice SAULQUIN, Responsable URC", 
                    "phone": "33 (0)2 40 67 99 00"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Centre Ren\u00e9 Gauducheau"
                }, 
                "investigator": [
                    {
                        "last_name": "Emmanuelle BOMPAS, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Fr\u00e9d\u00e9ric ROLLAND, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Damien VANSTEENE, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06189"
                    }, 
                    "name": "Centre Antoine Lacassagne"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "laurence.culine@sls.aphp.fr", 
                    "last_name": "Laurence CULINE, Directrice D\u00e9l\u00e9gu\u00e9e CIRCO", 
                    "phone": "33 (0)1 42 38 51 10"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75010"
                    }, 
                    "name": "H\u00f4pital Saint Louis"
                }, 
                "investigator": [
                    {
                        "last_name": "Christine LEMAIGNAN, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Damien POUSSEL, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patricia.tresca@curie.fr", 
                    "last_name": "Patricia TRESCA, MD", 
                    "phone": "33(0)1 56 24 56 32"
                }, 
                "contact_backup": {
                    "email": "ANNE.BLONDEL@curie.fr", 
                    "last_name": "Anne BLONDEL, CRA", 
                    "phone": "33(0)1 44 32 46 86"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75005"
                    }, 
                    "name": "Institut Curie"
                }, 
                "investigator": [
                    {
                        "last_name": "Sophie PIPERNO-NEUMANN, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Val\u00e9rie LAURENCE, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Laurent MIGNOT, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75014"
                    }, 
                    "name": "H\u00f4pital Cochin"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "o.zekri@rennes-unicancer.fr", 
                    "last_name": "Oussema ZEKRI, CRA Manager", 
                    "phone": "33 (0)2 99 25 31 32"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35042"
                    }, 
                    "name": "Centre Eug\u00e8ne Marquis"
                }, 
                "investigator": [
                    {
                        "last_name": "Pierre KERBRAT, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Christophe PERRIN, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Julien EDELINE, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Marie TALARMIN, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "louis.ferdinant.pepin@chb.unicancer.fr", 
                    "last_name": "Louis-Ferdinand PEPIN, MD", 
                    "phone": "33 (0)2 32 08 24 54"
                }, 
                "contact_backup": {
                    "email": "sabine.lorivel@chb-unicancer.fr", 
                    "last_name": "Sabine LORIVEL, CRA", 
                    "phone": "33 (0)2 32 08 29 28"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76038"
                    }, 
                    "name": "Centre Henri Becquerel"
                }, 
                "investigator": [
                    {
                        "last_name": "C\u00e9cile GUILLEMET, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jean Christophe THERY, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "stephanie.dupont-casquin@curie.net", 
                    "last_name": "St\u00e9phanie DUPONT-CASQUIN, Responsable UIRC", 
                    "phone": "33 1 47111853"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Cloud", 
                        "country": "France", 
                        "zip": "92210"
                    }, 
                    "name": "Institut Curie - H\u00f4pital Ren\u00e9 Huguenin"
                }, 
                "investigator": {
                    "last_name": "Laurence BOZEC, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mathieu.oriol@icloire.fr", 
                    "last_name": "Mathieu ORIOL, CRA", 
                    "phone": "33 477917071"
                }, 
                "facility": {
                    "address": {
                        "city": "St Priest En Jarez", 
                        "country": "France", 
                        "zip": "42270"
                    }, 
                    "name": "Institut de Canc\u00e9rologie Lucien Neuwirth (ICL)"
                }, 
                "investigator": {
                    "last_name": "Olivier COLLARD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "poublanc.muriel@claudiusregaud.fr", 
                    "last_name": "Muriel POUBLANC, Responsable URC", 
                    "phone": "33 (0)5 61 42 46 74"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "32052"
                    }, 
                    "name": "Institut Claudius Regaud"
                }, 
                "investigator": [
                    {
                        "last_name": "Christine CHEVREAU, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Carlos GOMEZ-ROCA, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "v.gillon@nancy-unicancer.fr", 
                    "last_name": "V\u00e9ronique GILLON, Responsable URC", 
                    "phone": "33 (0)3 83 59 85 74"
                }, 
                "facility": {
                    "address": {
                        "city": "Vandoeuvre Les Nancy", 
                        "country": "France", 
                        "zip": "54519"
                    }, 
                    "name": "Centre Alexis Vautrin"
                }, 
                "investigator": [
                    {
                        "last_name": "Maria RIOS, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ivan KRAKOWSKI, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nadia.amellal@igr.fr", 
                    "last_name": "Nadia AMELLAL, MD", 
                    "phone": "33 (0)1 42 11 66 70"
                }, 
                "contact_backup": {
                    "email": "rosa.dasilva@igr.fr", 
                    "last_name": "Rosa DA SILVA, CRA Manager", 
                    "phone": "33 (0)1 42 11 40 27"
                }, 
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94800"
                    }, 
                    "name": "Institut Gustave Roussy"
                }, 
                "investigator": [
                    {
                        "last_name": "Olivier MIR, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Axel LE CESNE, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Julien DOMONT, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "France"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial", 
        "other_outcome": {
            "measure": "Potential predictive factors for regorafenib response.", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "overall_contact": {
            "email": "n-penel@o-lambret.fr", 
            "last_name": "Nicolas PENEL, MD, PhD", 
            "phone": "+33(0)3 20 29 59 20"
        }, 
        "overall_contact_backup": {
            "email": "y-vendel@o-lambret.fr", 
            "last_name": "Yvette VENDEL, Project Manager", 
            "phone": "33 (0)3 20 29 59 18"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre Oscar Lambret - France", 
                "last_name": "PENEL Nicolas, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "AKH-Wien - Austria", 
                "last_name": "Thomas BRODOWICZ, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hannover Medical School", 
                "last_name": "Viktor GR\u00dcNWALD, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900743"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Growth modulation index in patients receiving regorafenib after randomization", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Toxicity according to NCI-CTC AE V4.0.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, every 4 weeks, up to the end of study"
            }, 
            {
                "description": "According to the RECIST 1.1", 
                "measure": "Progression-free rate at 3 and 6 months (PFR-3 and PFR-6)", 
                "safety_issue": "No", 
                "time_frame": "At month 3 and at month 6"
            }, 
            {
                "description": "According to the RECIST 1.1 Every 4 weeks, Up to 2 years", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Time from the date of randomization to the date of death from any cause", 
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Centre Oscar Lambret", 
        "sponsors": {
            "collaborator": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Centre Oscar Lambret", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}